Powered by GoogleTranslate

Occupational Safety and Health Administration OSHA

Citation 314205774/01001

InspectionReporting IDOpen DateSICEstablishment Name
314205774 0418100 10/27/2010 8069Medical Center Of Central Georgia, Inc.

CitationIssuance DateHazard Category
01001 02/23/2011 Unclass

Section 5(a)(1) of the Occupational Safety and Health Act of 1970: The employer did not furnish employment and a place of employment which were free from recognized hazards that were causing or likely to cause death or serious physical harm to employees in that employees were exposed to the hazard of exposure to cytotoxic/antineoplastic/chemotherapy drugs: a)The employer did not ensure that employees working with cytotoxic drugs(chemotherapy drugs) such as, but not limited to L-asparginase, carboplatin, cyclophosphamide, cytarrabine, daunorubicin, doxorubicin, etoposide, fluorouracil, ganciclovir, hydroxyurea, ifosfamide, medroxyprogestrone, mercaptopurine, methotrexate, tamoxifin, thioguanine, vinblastine, vincristine, and zidovudine were trained in proper handling procedures and/or spill procedures, work practice controls, engineering controls, and personal protective equipment. b)Employees were not included in a medical surveillance program to include pre-placement medical exams, periodic exams, postexposure examinations, and exit exams. Among other methods, one feasible and acceptable abatement to correct this hazard is to develop a written hazardous drug safety and health plan by following the American Society of Hospital Pharmacist Technical Assistance Bulletin.e

Thank You for Visiting Our Website

You are exiting the Department of Labor's Web server.

The Department of Labor does not endorse, takes no responsibility for, and exercises no control over the linked organization or its views, or contents, nor does it vouch for the accuracy or accessibility of the information contained on the destination server. The Department of Labor also cannot authorize the use of copyrighted materials contained in linked Web sites. Users must request such authorization from the sponsor of the linked Web site. Thank you for visiting our site. Please click the button below to continue.